The four disorders studied are frequently sidelined in health policy because they kill relatively few people compared with cardiovascular disease, cancer, or diabetes. Yet they are among the leading causes of years lived with disability worldwide, generating recurring treatment needs, diminished work capacity, and cascading productivity losses that accumulate over decades of life. Anxiety and depressive disorders affect hundreds of millions of people globally and are disproportionately diagnosed in women; migraine is one of the most prevalent neurological conditions on the planet and affects women at roughly two to three times the rate of men; and rheumatoid arthritis, an autoimmune disease that progressively damages joints and erodes functional capacity, also strikes women far more often. In Mexico, where the health system is segmented across multiple social insurance schemes and large swaths of the population face gaps in access and financial protection, the economic consequences of these conditions were essentially unquantified at the national level before this analysis.

The research team, led by co-first authors Carlos Manuel Guerrero-López and Edson Serván-Mori, performed a full cost-of-illness analysis from a societal perspective, covering adults aged twenty years and older between 2005 and 2021. In health economics, the societal perspective is the most encompassing lens available: it counts not only what the health system spends but also what patients, families, and the broader economy lose. Direct costs in the study were estimated by combining condition-specific prevalence figures from the Global Burden of Disease Study 2021 with normative per-case treatment costs derived from Mexican national clinical guidelines and official government cost sources. This prevalence-based, guideline-anchored approach means the cost estimates reflect what standard care should cost, expressed in 2021 international dollars to allow purchasing-power-adjusted comparisons.

The treatment of indirect costs was where the methodological ambition of the study becomes most apparent. Lost productivity is the hardest component of disease burden to value, and estimates can vary enormously depending on the economic framework chosen. To address this, the researchers used three complementary approaches. The first was the Human Capital Approach, a classical method that values lost production by predicting annual labour income from the National Survey of Occupation and Employment, a nationally representative employment survey conducted by Mexico’s statistics institute. The second was a GDP-per-capita benchmark that values each disability-adjusted life year, or DALY, lost at one gross domestic product per capita, a convention widely used in global burden-of-disease economics. The third and most expansive was a willingness-to-pay approach, which assigned each statistical life year a monetary value using the value of a statistical life year transferred to Mexico following Organisation for Economic Co-operation and Development methods. By triangulating across all three, the team sought to show that their central finding, the gender gap, does not depend on any single set of valuation assumptions.

The scale of the findings is difficult to overstate. Across the study period, the four disorders accounted for 28.8 million disability-adjusted life years lost in Mexico. Migraine emerged as the most prevalent of the four conditions, a reminder that a headache disorder often dismissed as trivial is in fact a mass-scale public health problem. But prevalence is not the same as cost: depressive disorders generated the highest direct medical costs, totalling 310.5 billion international dollars, and also contributed the largest share of indirect costs, at 41.1 percent. The indirect cost totals diverged dramatically by valuation method, underscoring how sensitive such estimates are to economic framing. Under the conservative Human Capital Approach, lost productivity was valued at 106.8 billion international dollars; under the GDP-per-capita benchmark, it rose to 582.2 billion; and under the willingness-to-pay framework, it reached a staggering 2.9 trillion international dollars. Combining the direct costs with the midpoint GDP-per-capita valuation of indirect costs, the total economic burden of the four disorders over sixteen years came to approximately 1.2 trillion international dollars, a figure that dwarfs most line items in Mexican health budgets.

What elevates the study from a routine costing exercise to an equity analysis is its consistent gender lens, and here the pattern was unambiguous. Women carried a greater burden than men across all four conditions and under all three valuation methods, without exception. Total indirect costs borne by women were 2.0 times higher than those borne by men for anxiety disorders, 2.1 times higher for depressive disorders, 2.2 times higher for migraine, and 3.8 times higher for rheumatoid arthritis. The arthritis figure is especially striking and reflects a compounding of factors: the disease is far more common in women, tends to be disabling over long durations, and its costs accumulate across both paid employment and unpaid domestic labour, the latter of which is systematically undervalued in conventional human capital calculations. The researchers note that these ratios held steady throughout the study period, from 2005 through 2021, spanning economic cycles, health system reforms, and the COVID-19 pandemic.

The COVID-19 pandemic deserves particular mention because the study period captures its onset and immediate aftermath. Mental health deteriorated markedly worldwide during the pandemic, with anxiety and depression prevalence rising sharply in 2020 and 2021, and women shouldered a disproportionate share of both the psychological toll and the disruptions to employment and caregiving. While the study’s methods are prevalence-based and normative rather than tracking individual patient trajectories, the inclusion of the pandemic years means the estimates likely capture at least some of the surge in mental disorder burden, making the recorded gender inequities arguably conservative. The researchers also observed that in Mexico’s segmented system, in which workers in the formal sector are covered by institutions such as the Mexican Institute of Social Security while others rely on separate public or private pathways, continuity of care for chronic mental and musculoskeletal conditions varies widely, amplifying the downstream economic consequences for the most vulnerable.

The authors are careful about what their numbers do and do not represent. Because per-case costs were derived from normative clinical guidelines rather than observed claims data, the figures describe what care should cost if guidelines were followed, which in practice may understate the true societal burden in a system with significant under-treatment. The three valuation methods span a wide range precisely because the economics of valuing disability and lost life quality remain contested. Yet the robustness of the gender disparity across this entire range is the study’s central strength: no reasonable set of assumptions erases it. The team adhered to the Consolidated Health Economic Evaluation Reporting Standards 2022 guidelines and reported the work transparently, with extensive supplementary materials breaking down direct and indirect costs by condition and year. Funding came from the Mexican Association of Pharmaceutical Research Industries, though the funder played no role in study design, analysis, or the decision to publish, and the authors declare no competing interests.

The policy implications extend well beyond Mexico’s borders. Low- and middle-income countries with fragmented health systems share Mexico’s structural features: multiple insurers, uneven drug availability, thin mental health infrastructure, and weak financial protection against long-duration chronic illness. The study argues that mortality-centred planning systematically deprioritises conditions that disable rather than kill, and that this bias is itself a gendered phenomenon given that the disabling conditions in question disproportionately affect women. The researchers call for gender-responsive priority setting in prevention, diagnosis, and treatment continuity, alongside stronger financial protection and better information systems capable of supporting equity-oriented resource allocation. In practical terms, that means screening and treating depression and anxiety as core chronic disease management rather than optional extras, ensuring reliable access to migraine and rheumatoid arthritis medications, and designing benefit packages that recognise how these conditions interact with women’s dual roles in paid and unpaid work.

There is also a broader conceptual lesson for health economics itself. By running three valuation frameworks side by side, the study demonstrates that choices about how to value a life year or a lost day of work are not technical trivia; they determine whether a trillion-dollar burden registers as a rounding error or a crisis. Under the most conservative method, the indirect costs of these four conditions appear modest; under the willingness-to-pay framework they exceed the value of many national economies’ annual output. The authors’ insistence on reporting all three, and on showing that the gender pattern survives all of them, offers a template for future burden-of-disease research in other countries where women’s economic contributions, formal and informal, remain undercounted.

For the millions of Mexican women living with depression that goes untreated, migraines that force missed workdays, or joints progressively stiffened by rheumatoid arthritis, the study’s findings will not come as news. What is new is the formal accounting: a documented, sixteen-year, 1.2 trillion international dollar demonstration that the economics of chronic disability in Mexico are, inescapably, the economics of gender inequality. Turning that accounting into policy, the researchers conclude, will require treating anxiety, depression, migraine, and rheumatoid arthritis not only as clinical problems but as matters of health equity, deserving of the same urgency and investment that Mexico and other countries devote to their deadliest diseases.

Mexico’s journey toward comprehensive health insurance coverage offers an intriguing case study. For decades, the country has been beset by stark inequalities in health access, influencing the lives of millions across various socioeconomic strata. A century ago, health insurance in Mexico was almost nonexistent for the lower-income population. However, political wills have shifted, resulting in the expansion of programs intended to include previously marginalized citizens. The introduction of Seguro Popular in the early 2000s marked a critical turning point, promising coverage to underserved communities. Yet, despite these progressive movements, significant disparities persist, highlighting the complex nature of health insurance in practice.

Examining the data reveals that progress toward UHC in Mexico has been a double-edged sword. While the percentage of the population with health insurance has dramatically increased, the quality and extent of coverage remain inconsistent. The findings from Serván-Mori et al. underscore that while more people have gained access to health services, many continue to face barriers such as high out-of-pocket expenses and limited access to essential health services. This phenomenon raises questions about the true nature of “coverage” and provokes discussions about what it means to achieve true UHC.

A significant concern expressed in their study is the persistence of regional disparities. Different regions in Mexico experience vastly different levels of access to healthcare resources. For instance, urban areas typically fare better in both the availability and quality of health services compared to rural regions. This urban-rural divide is not merely an issue of geographical distance; it embodies deeper systemic inequalities that often correlate with economic and social factors. For many, this translates to a healthcare system that is not uniformly accessible or equitable, and this inequality poses a serious threat to UHC goals.

Moreover, the study emphasizes the demographic challenges facing Mexico’s health insurance landscape. The aging population, coupled with rising prevalence of chronic conditions such as diabetes and hypertension, adds pressure to the health system. Health insurance coverage must evolve to meet the complex needs of a diverse population. A failure to adapt might exacerbate existing inequalities and hinder overall progress toward UHC. The authors contend that strategic policy interventions are paramount to align the healthcare ecosystem with these demographic realities.

The political context within which health policies are formulated plays a pivotal role in shaping health insurance coverage. Political commitment to UHC is essential, yet often fluctuates with changes in administration. The recent restructuring of Mexico’s health system has led to uncertainty and confusion among beneficiaries regarding their coverage. This upheaval not only undermines trust in public health initiatives but also distracts from addressing fundamental inequalities that must be tackled for UHC success. The need for sustained commitment and transparent governance is vital for ensuring that the gains made are preserved and built upon.

Emergency situations, like the COVID-19 pandemic, underscore the vulnerabilities within the health system and expose inequalities that were perhaps less visible before. The pandemic intensified examination of health coverage as citizens sought urgent care amid an overwhelmed system. Serván-Mori et al. argue that this crisis must serve as a learning opportunity. They emphasize that a robust health insurance framework can help protect populations during such emergencies, but further investment in healthcare infrastructure is essential for future resilience against similar crises.

Public perception also profoundly impacts health insurance utilization. Studies indicate that many Mexicans remain unaware of their insurance rights, which can deter them from seeking care even when services are available. Campaigns to educate the population about their entitlements and the importance of medical care cannot be overemphasized. Empowering citizens with knowledge is vital for realizing UHC and improving overall health outcomes.

In examining the pathway toward UHC2030, the analysis provided by Serván-Mori et al. reveals critical nuances regarding financing mechanisms. The authors advocate for diversified funding streams to ensure sustainability and effectiveness of health insurance coverage. Relying solely on government funding is insufficient given Mexico’s economic challenges. The exploration of innovative funding solutions—such as public-private partnerships or international aid—may be essential for enhancing service delivery and expanding access.

Significantly, the study also raises concerns about quality of care. Gaining access to health insurance is crucial, but without quality services, mere coverage is insufficient. The authors caution that a focus on quantity over quality could lead to disillusionment among beneficiaries, ultimately dissuading them from utilizing available healthcare services. Quality assurance measures must be embedded within the reform agenda to ensure that health services meet national and international standards.

As the health sector in Mexico continues to evolve, the push toward UHC2030 will demand concerted efforts on multiple fronts. Stakeholders must engage in collaborative approaches that consider the unique challenges of diverse populations across the country. Policymakers, healthcare providers, and civil society must partner effectively to champion comprehensive health reforms. This collective action, rooted in equity and transparency, could catalyze progress toward a more just health system.

In conclusion, the work of Serván-Mori et al. highlights that achieving universal health coverage in Mexico is not merely a checkbox on a political agenda; it demands continuous introspection, action, and the advocacy of all stakeholders involved. The intricate web of health insurance, access, quality care, and public education must be navigated with diligence and urgency to ensure that the vision of UHC2030 is not just an aspiration but a tangible reality for all Mexicans. The importance of understanding these dynamics can resonate far beyond the borders of Mexico, offering valuable insights for nations worldwide engaged in similar struggles toward equitable health access.

Subject of Research: Health insurance coverage in Mexico

Article Title: Health insurance coverage in Mexico: progress, inequalities and remaining challenges towards UHC2030

Article References:
Serván-Mori, E., Cerecero-García, D., Meneses-Navarro, S. et al. Health insurance coverage in Mexico: progress, inequalities and remaining challenges towards UHC2030.
Health Res Policy Sys 23, 145 (2025). https://doi.org/10.1186/s12961-025-01405-w

Image Credits: AI Generated

DOI: 10.1186/s12961-025-01405-w

Keywords: Universal Health Coverage, Health Insurance, Mexico, Health Inequalities, UHC2030